Organ Preservation Solutions Market – Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 – 2019
Transparency Market Research is Published new Market Report “Organ Preservation Solutions Market (By Solutions-Viaspan, Custodiol HTK, Renograf, Hypothermosol, Perfadex, Lifor, HBS Solution, siRNA Transplant Solution and Others, and By Preservation Techniques- Hypothermic Perfusion Preservation, Static Cold Storage and Others) – Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 – 2019,” in 2012, the global organ preservation solutions market was valued at USD 0.06 billion and is expected to grow at a CAGR of 16.5% during the forecast period 2013 to 2019 to reach a market value of USD 0.20 billion by 2019.
Browse Organ Preservation Solutions Market Report with Full TOC: http://www.transparencymarketresearch.com/organ-preservation-solutions.html
Organ preservation solutions help in preserving organs for long when they are not inside the living body, which makes them vulnerable to environment outside the human body.Organs that are removed from the human body are preserved using these solutions for various purposes such as organ transplant procedures and research and development of drugs and biologics. The global market for organ preservation solutions has been estimated to grow at the rate of 16.5% during the forecast period 2013 to 2019. This growth will be primarily driven by the increasing number of patients who are awaiting organ transplants, since these preservation solutions will enable survival of the organs outside the human body post donation by living or deceased donors.
In addition, the rising incidences of organ failure in the patient population owing to changes in lifestyles such as smoking, alcohol and fast food consumption, along with rise in geriatric population, especially in developed nations such as U.S. and U.K., will also propel the growth of this market. Likewise, increase in per capita healthcare expenditure and the improving reimbursement scenarios for organ transplant procedures in various nations such as U.S., U.K. and India will also support the growth of this market. This report studies the market foresight major solutions for preserving organs, amongst which Via span and Custodiol together account for the majority share (over75%) of total market in terms of revenue. During the forecast period 2013 to 2019, the Custodiol market is expected to grow at the highest CAGR of 17.1%. This growth is attributed to its extensive utilization for preserving various organs such as kidney and liver, since it is capable of preserving multiple organs unlike other solutions including Perfadex and HBS solution.
The different techniques utilized to preserve organs are static cold storage (SCS),hypothermic perfusion preservation (HPP) and others. HPP is a machine perfusion technique and maintains continuous supply of the solution needed by organs, unlike SCS that does not allow continuous contact of the organ with the solution. This property increases the survival duration of organs which will in turn augment its demand in the market. The HPP market is expected to grow at a CAGR of 19.2% during the forecast period 2013 to 2019.
The European region accounted for the largest share in terms of revenue of the total global organ preservation solutions market in 2012, and is expected to grow at the highest CAGR of 17.3% during the forecast period 2013 to 2019. This is due to the presence of a large number of organ donors in the region. For instance, in 2011 total number of deceased organ donors in the U.K. was around 1,056 according to the European Commission (EC). Also, the European region exhibited highest rate of aging of population which will also help propel the growth of this market. The global organ preservation solutions market is ruled by players such as Teva Pharmaceutical Industries Ltd.,Bristol-Myers Squibb, Dr. Franz KohlerChemie GmbH, XVIVO Perfusion AB and BioLife Solutions, Inc. These companies together accounted for around 90% of the total market revenue in 2012. Some other important players operating in the market include CryoLife, Inc., Lifeline Scientific, Claris Lifesciences Ltd., 21st Century Medicine and BioTime, Inc.
Organ Preservation SolutionsMarket, by Solution
- Custodiol HTK (Histidine-Tryptophan-Ketoglutarate)
- Human bioSystem (HBS) Solution
- siRNA Transplant Solutions
Organ Preservation Solutions Market, by Technique
- Hypothermic Perfusion Preservation (HPP)
- Static Cold Storage (SCS)
Organ Preservation Solutions Market, by Geography
- North America
- Rest of the World (RoW)
Drugs of Abuse Testing Market is Expected to Reach USD 3.4 Billion Globally in 2018: Transparency Market Research
According to a new market report published by Transparency Market Research “Drugs of Abuse Testing Market (Sample Based Testing – Urine, Saliva and Hair Onsite and laboratory Testing) – Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 – 2018” the global drugs of abuse testing market was valued at USD 2.6 billion in 2012 and is expected to grow at a CAGR of 4.8% from 2013 to 2018, to reach an estimated value of USD 3.4 billion in 2018.
Browse the full Report with TOC: http://www.transparencymarketresearch.com/drugs-abuse-testing-market.html
In various countries, government rules & regulations are supporting drugs of abuse testing market to grow, as they have outlined essential drug testing at workplace, such as in the US, Japan, Australia and the UK. As a result, this market is expected to grow at a CAGR of about 4.8% during 2013 – 2018.
Some of the key driving factors for the drugs of abuse testing market are global rising consumption of illicit drugs, adoption of drug of abuse (DOA) testing at organizational level, increased production of illicit drugs and their trade and increasing death rates/road accidents due to drug abuse. However, the market faces some restraints such as social concerns associated with illicit drugs testing, legalization of various drugs, and economic volatility and cost concerns.
North America, including the US has the largest drugs of abuse testing market and is also the fastest growing drugs of abuse testing market. Some of the fastest growing markets for drugs of abuse testing are US, UK, Japan, Germany and other European countries. According to UNODC report 2013, number of illicit drug users is estimated to increase from 167 million in 2009 to 315 million people in 2011. This corresponds to 3.6% to 6.9% of global adult population and cannabis, opioids and opiates were most commonly used illicit drugs. In various countries, including America and Europe countries, organizations are conducting drug screening test at various levels, such as pre-employment screening, random drug/alcohol screening, post incident drug/alcohol screening and abstinence monitoring. In many countries, government rules & regulations are also supporting the growth of drugs of abuse testing market, as they have outlined essential drug testing at workplace, such as in the US, Japan, Australia and the UK. This has emerged as a key driver for the market.
Urine is the largest sample which is diagnosed in the drugs of abuse testing market and it is expected to grow at a CAGR of about XX% during 2013 – 2018. The other major samples for drugs of abuse testing are Saliva and Hair. Laboratory drug screening test requires a trained and skilled person to provide an accurate result and involves in-depth analysis. In laboratory screening test, usually the test is reconfirmed using gas chromatography/mass spectrometry or any other superior techniques to provide accurate results. On-site drug screening test gives results on the spot and it is generally preferred for those who take the drug test at home, workplace and educational institutions. The most common specimens used in on-site drug testing are urine, saliva and hair. Nowadays, commercially-available on-site screening test kits are usually designed for urine and saliva specimens only.
Roche Diagnostics is the leading player in the global drugs of abuse testing market. Other major players of drugs of abuse testing market include Quest Diagnostics, LabCorp, Alere and Abbott Laboratories and others.
The global drugs of abuse testing market is segmented as follows:
Drugs of Abuse Testing Market, By Sample
Drugs of Abuse Testing Market, By Types
- Laboratory Drug Test
- On-site Screening Test
Drugs of Abuse Testing Market, by Geography
- North America
- Asia Pacific
- Rest of the World (RoW)
According to a new market report published by Transparency Market Research “Ophthalmic Drugs Market (Dry eye, Anti-glaucoma, Anti allergy/ inflammatory/ infective, Retinal Drugs) – Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 – 2018” the global ophthalmic drugs market was valued at USD 16 billion in 2012 and is expected to grow at a CAGR of 5.2% from 2013 to 2018, to reach an estimated value of USD 21.6 billion in 2018.
Browse the full Report with TOC: http://www.transparencymarketresearch.com/ophthalmic-drugs-market.html
Globally, the ophthalmic drugs market is witnessing significant growth due to increasing prevalence of eye disorders such as diabetic retinopathy and macular degeneration. As a result, this market is expected to grow at a CAGR of about 5.2% during 2013 – 2018.
Some of the key driving factors for the ophthalmic drugs market are rising prevalence of global aging population, increasing government initiatives towards healthcare infrastructure in developing countries (such as India and China), technological changes in drug delivery technique, and increasing prevalence of lifestyle associated diseases. However, the market faces some restraints such as lack of awareness among people regarding eye disorders, drying pipeline of ophthalmic drugs, patent expiration of blockbuster ophthalmic drugs and absence of health insurance in developing countries.
North America, including the US has the largest ophthalmic drugs market. Asia is the fastest growing ophthalmic drugs market. Some of the fastest growing markets for ophthalmic drugs are China, India, other countries in South East Asia and the Eastern Mediterranean. As per WHO estimates in 2010, in the next nine years, the number of blind people aged 50 years and above will grow in these regions, thereby increasing the demand for ophthalmic drugs. On the other hand, in developed regions such as North America and Western Europe, rising efforts towards prevention of blindness among the aging population has emerged as a key driver for the market.
Browse full PDF with TOC: Ophthalmic Drugs Market- Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 – 2018
Glaucoma has the largest market share in the ophthalmic drugs market and it is expected to grow at a CAGR of about 4.2% during 2013 – 2018. Various ophthalmic drug companies are increasing their focus on combination therapy, which involves use of more than one medication for specific retinal disorders. Most of these combination therapies are used as first line treatment in patients with high level of intraocular pressure. Combination therapy has various advantages over traditional medication such as reduced frequency of eye drop application, improved patient compliance and efficacy.
Novartis (Alcon) is the leading player in the global ophthalmic drugs market while other major players include Allergan, Santen, Pfizer, Merck and Roche.
The global ophthalmic drugs market is segmented as follows:
Ophthalmic Drugs Market, By Treatment Drugs
- Dry Eye Drugs
- Retinal Drugs
- Anti-inflammatory/allergy/infective Drugs
- Anti-glaucoma Drugs
Ophthalmic Drugs Market, By Types
- Prescription Drugs
- OTC Drugs
Ophthalmic Drugs Market, by Geography
- North America
- Asia Pacific
- Rest of the World (RoW)
Browse more market research reports: Transparency Market Research
Global Cord Blood Banking Services Market is Expected to Reach USD 15.2 Billion in 2019: Transparency Market Research
According to a new market report published by Transparency Market Research, “Cord Blood Banking Services Market (Private and Public Cord Blood Banks) – Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 – 2019″, the global cord blood banking services market was valued at USD 12.40 billion in 2012 and is expected to grow at a CAGR of 5.6% from 2013 to 2019, to reach an estimated value of USD 15.23 billion in 2019.
Browse the full report with complete TOC: http://www.transparencymarketresearch.com/cord-blood-banking-services.html
Cord blood banking (CBB) is one of the fastest growing segments of the healthcare industry. Factors such as increasing awareness, initiatives taken by governments to regulate the CBB industry, an increasing number of diseases that can be treated using stem cell therapy and growing concerns about developing worldwide cord blood inventory will have an impact on the current model of the cord blood banking industry.
The global cord blood banking services market is segmented on the basis of type of service vendor and geography. Based on service vendor type the cord blood banking market is classified into private cord blood banks and public cord blood banks. The market share of private cord blood banks is larger than the public cord blood banks as private banks charge the service right from the collection of the cord blood followed by storage and processing charges, spends more on advertising and incentives as compared to public banks. It is expected that the global market for private banks will reach USD 11.58 billion in 2019 with the market growing at CAGR of 1.9% from 2013 to 2019. The shift from storing cord blood in private banks to public banks is growing the market share of public cord blood banks globally.
The United States, and some of the European countries such as the U.K. and Spain, are leading in cord blood banking services. Asian countries like China and India are emerging markets with higher population growth rate. UAE, Qatar and Saudi Arabia are some of the lucrative markets in RoW.
North America currently dominates the market but in future developing countries in Asia will lead the market. Growth drivers in the North American market are increasing awareness about the cord blood banking services, stem cell therapy and affordable cost.
Some of the key market players operating in this market include Cord Blood America, Inc., NeoStem, Inc., Cryo-Cell International, Inc., Cord Blood Registry Systems, Inc. and China Cord Blood Corporation.
The global cord blood banking services market is segmented as follows:
- Based on Type of Service Vendor
- Private cord blood banks
- Public cord blood banks
- Based on Geography
- North America
- United States
- New Zealand
- Rest of the World
- Middle Eastern Countries
- North America
Released New Report: Global Equine Healthcare Market is Expected to Reach USD 24.5 Billion in 2019: Transparency Market Research
According to a new market report published by Transparency Market Research “Equine Healthcare Market (Diagnostic Products, Therapeutic Products and Supplement Products) – Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 – 2019″ the global equine healthcare market was valued at USD 26.6 billion in 2012 and is expected to decline at a CAGR of -1.2% from 2013 to 2019, to reach an estimated value of USD 24.5 billion in 2019.
Browse the full report with complete TOC: http://www.transparencymarketresearch.com/equine-healthcare-market.html
The equestrian industry results in a substantially high economic impact as a result of one of the industry’s primary activity – horse racing and betting; horse racing and betting comprises ~20% share of the global betting/gambling market. The equestrian industry thus generates a multiplier effect resulting into turnover of over ~USD 500 billion per year. Due to the ‘trickle-down effect’ of flow of the economic impact of the overall equestrian industry, multiple support or secondary markets exist and sustain; the equine healthcare market is among such support or secondary markets. As the base of existence of the equestrian industry is the population/number of horses worldwide, any change in the equine population impacts the equestrian industry and the support or secondary markets such as the equine healthcare market. Many experts and corroborating statistical data reveals that the global equine population is expected to decline over the years till 2019; consequentially, the equine healthcare market too is expected to decline by 1.2% over six years, from 2013 to 2019, to reach an estimated value of USD 24,527.8 million in 2019.
Equine healthcare market comprises of various ‘product market segments’ in context of various products used for treatment of equine-specific healthcare conditions, diagnosis of equine-specific healthcare conditions and also supplements and protection products used for upkeep and maintenance of a horse. Thus the three prime segments of the equine healthcare market are equine diagnostic products, equine therapeutic products and equine supplement products.
In context of equine (pregnancy and gestation) diagnostic products, there are two key categories of products used namely UltraSound devices and equine urine test kits. Of the two categories, equine urine test kits are affordable and easy-to-use and interpret the results and also help overcome a prime limitation of UltraSound devices i.e. the kits are non-invasive in nature. Thus, we expect equine urine test kits to be increasingly preferred by the veterinarians and the end-users, going forward. Also, the equine urine test kit is a unique product to the equine species and cannot be substituted by the urine test kits for humans. Therefore, we estimate the urine test kits market to be a niche opportunity that is likely to be encashed by newer entrants thus expanding the market and driving growth of the equine diagnostic products market.
In terms of geographical markets of the equine healthcare market, the Asia-Pacific region is touted to be the ‘next growth story’. A constituent of Asia-Pacific namely the Australian market is among the leading ‘horse producing/breeding’ countries. Additionally, China is expanding capacity and investing in horse racing and betting by importing quality breeds from other countries. China is thus intent on maintaining particularly race-horse breeds. As race-horses require additional and specific supplement and protection products, therapeutic and also diagnostic products, sales of all these products is thus expected to be high in the Asia-Pacific market. Therefore the afore-mentioned factors are likely to drive growth of the Asia-Pacific market.
The global equine healthcare market is segmented as follows:
Equine Diagnostic Products Market, by Type
- Equine Pregnancy and Gestation Diagnostic Products Market
- Equine Genotype Analysis Products Market
Equine Therapeutics Product Market, by Type
- Equine Vaccines Market
- Equine Antibacterials Market
- Equine Antivirals Market
- Equine Antiprotozoals/Dewormers Market
- Equine Dopamine Agonists Market
- Equine Anti-inflammatory Drugs Market
- Equine Laxatives Market
Equine Supplement Products Market, by Type
- Equine Performance Supplement Market
- Equine Protection Products Market
- Equine Prosthetics Market
Equine Healthcare Market, by Geography
- North America
- Rest of World (RoW)
Healthcare Contract Research Outsourcing (HCRO) Market is expected to reach USD 65.03 billion by 2018: Transparency Market Research
According to a new market report published by Transparency Market Research “Healthcare Contract Research Outsourcing Market (Contract Research Organizations, Clinical Data Management, Clinical Trial Laboratories, Regulatory Medical Writing, Academic Medical Center) – Global Industry Analysis, Size, Share, Trends and Forecast, 2012 – 2018”, the global healthcare contract research outsourcing market was valued at USD 25.08 billion in 2011 and is forecasted to reach USD 65.03 billion by 2018, growing at a CAGR of 14.7% from 2012 to 2018.
Browse the full report: http://www.transparencymarketresearch.com/hcro-market.html
Global pharmaceutical and medical device industry is slowly transitioning from an integrated process model to outsourcing model, where pharmaceutical companies outsource various processes including clinical trials, medical writing, and regulatory processes to their contract research partners, who have relevant expertise. Major business segments outsourced include clinical trials and central lab services.
Contract research outsourcing market is propelled mainly by depleting product pipelines, patent expiries in the near future and declining productivity, especially in the last decade. Expertise available with contract research partners, reduced research process duration, cost savings, flexible pricing models and research globalization options are observed as major advantages for the pharmaceutical companies outsourcing their research processes to contract research units.
North America accounted for majority market share at 64.1% in 2011, followed by Europe and Asia. Asia has emerged as the fastest growing region in offering contract research outsourcing services. The growth of this region is supported by presence of large number of Contract Research Organizations (CROs), cost-effectiveness and expertise. Key players dominating the global market include Quintiles, Covance, PPD, Parexel, CRL, Icon Plc, Medidata Solutions and InVentiv Health.
Browse full PDF with TOC: Healthcare Contract Research Outsourcing Market
The study presents a comprehensive assessment of the stakeholder strategies and winning imperatives for them by segmenting the contract research outsourcing market as below:
Global healthcare contract research outsourcing market by services
Clinical trial services
- Drug discovery
- Preclinical studies
- Phase I trial services
- Phase II trial services
- Phase III trial services
- Phase IV trial (Post marketing surveillance) services
- Regulatory services
- Medical writing services
- Clinical Data Management (CDM) services
Global healthcare contract research outsourcing market by destination research groups
- Contract Research Organizations (CROs)
- Clinical Trial Laboratories (CTL)
- Academic Medical Centers (AMCs)
Global healthcare contract research outsourcing market by Geography
- North America
Related & Recently Published Reports by Transparency Market Research
Liver Diseases Therapeutics Market: http://www.transparencymarketresearch.com/liver-diseases-therapeutics.html
General Medicine Education Publishing Market: http://www.transparencymarketresearch.com/general-medicine-education-publishing.html
mHealth Market: http://www.transparencymarketresearch.com/mobile-health-market.html
Healthcare Cloud Computing Market- Global Industry Analysis, Size, Share, Trends and Forecast 2012 – 2018
According to a new market report published by Transparency Market Research “Cloud Computing Market In Healthcare Industry (IaaS, SaaS, PaaS, CIS, NCIS, PACS, EMR, RIS) – Global Industry Analysis, Size, Share, Trends and Forecast, 2012 – 2018” the global cloud computing market in the healthcare industry was valued at USD 1.82 billion in 2011 and is expected to reach USD 6.79 billion by 2018, growing at a CAGR of 21.3% from 2012 to 2018.
Browse full report with TOC: http://www.transparencymarketresearch.com/healthcare-cloud-computing.html
The report provides the market estimate and forecast in terms of revenue for the global cloud computing market in healthcare industry. A detailed analysis of the market trends, current scenarios and future trends from 2012 to 2018 is available in the report. The market is analyzed by using concepts such as market dynamics including drivers, restraints and opportunities along with their impact analysis and market attractiveness analysis.
The market is segmented on the basis of cloud types into: Public, private and hybrid cloud. A detailed trend analysis of all the segments with market evaluation in terms of revenue generated with respect to the applications and geography is available in this report.
The market is also segmented on the basis of geography into: North America, Europe, Asia and rest of the world (RoW) regions. Geography wise, market evaluation is available in terms of revenue from 2012 to 2018.
A competitive analysis of the market players involved is also available in the report. Some of the major players of this market include: CareCloud, ClearDATA Networks, Merge Healthcare, Agfa Healthcare, IBM Corporation, Microsoft, Carestream Health, Oracle Corporation and others. Company overview, financial overview, business strategies, SWOT analysis, recent developments and product portfolio for each of the market players is also highlighted in the report.
The study presents a comprehensive assessment of the stakeholder strategies and their winning imperatives by segmenting the cloud computing market in healthcare industry as below:
Global cloud computing market in healthcare industry by service models
- Infrastructure-as-a-Service (IaaS)
- Platform-as-a-Service (PaaS)
- Software-as-a-Service (SaaS)
Global cloud computing market in healthcare industry by pricing models
- Spot pricing or subscription model
- Pay-as-you-go model
Global cloud computing market in healthcare industry by end user applications
Clinical Information systems (CIS) cloud computing market
Non-Clinical Information systems (NCIS) cloud computing market
- Claims management
Global cloud computing market in healthcare industry by geography
- North America